Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.46 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28419499 | 0.93 | FLT3 (0.47) | FLT3LMNAMAPTTP53TSHR | |
| SCHEMBL73436 | 0.91 | F2RL3 (0.46) | FLT3RAD51LMNAMAPTTP53 | |
| SCHEMBL11013461 | 0.86 | FLT3 (0.57) | FLT3LMNAMAPTTP53TSHR | |
| SCHEMBL13539252 | 0.86 | LMNA (0.53) | LMNAMAPTTP53TSHRRAB9A | |
| Water SCHEMBL11011696 | 0.85 | FLT3 (0.56) | FLT3LMNAMAPTTP53TSHR | |
| SCHEMBL29056678 | 0.84 | LMNA (0.49) | FLT3LMNAMAPTTP53TSHR | |
| SCHEMBL29924814 | 0.84 | LMNA (0.49) | FLT3LMNAMAPTTP53TSHR | |
| SCHEMBL74473 | 0.84 | TP53 (0.46) | FLT3LMNAMAPTTP53TSHR | |
| SCHEMBL29925273 | 0.83 | LMNA (0.48) | LMNAMAPTTP53TSHRRXFP1 | |
| SCHEMBL774163 | 0.83 | MAPT (0.70) | FLT3LMNAMAPTTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150612-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | Ambit Biosciences Corporation (US) | 2017-04-05 | — | — | EP | claimed |
| EP-2496584-B1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | AMBIT BIOSCIENCES CORP (US) | 2016-09-21 | — | — | EP | claimed |
| US-9284332-B2 | Process for the preparation of imidazo[2,1-B][1,3]benzothiazole derivatives | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-15 | — | — | US | claimed |
| US-20130005966-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | AMBIT BIOSCIENCES CORP. (US) | 2013-01-03 | — | — | US | claimed |
| EP-2496584-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | Ambit Biosciences Corp. (US) | 2012-09-12 | — | — | EP | claimed |
| WO-2011056939-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | AMBIT BIOSCIENCES CORP. (US) | 2011-05-12 | — | — | WO | claimed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3559006-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180256586-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-09-13 | — | — | US | disclosed |
| WO-2018118598-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| EP-3150612-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | Ambit Biosciences Corporation (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3150612-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | Ambit Biosciences Corporation (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2201018-A2 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-{4-Ý7-(2-MORPHOLIN-4-YL-ETHOXY)IMIDAZOÝ2,1-B¨Ý1,3¨BENZOTHIAZOL-2-YL¨PHENYL}UREA, COMPOSITIONS THEREOF, AND USES THEREWITH | Ambit Biosciences Corporation (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010054058-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE | AMBIT BIOSCIENCE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20090131426-A1 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-UREA, COMPOSITIONS THEREOF, AND USES THEREWITH | AMBIT BIOSCIENCES | 2009-05-21 | — | — | US | disclosed |
| WO-2009038757-A2 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-{4-[7-(2-MORPHOLIN-4-YL-ETHOXY)IMIDAZO[2,1-B][1,3]BENZOTHIAZOL-2-YL]PHENYL}UREA, COMPOSITIONS THEREOF, AND USES THEREWITH | AMBIT BIOSCIENCES CORPORATION (US) | 2009-03-26 | — | — | WO | disclosed |
| EP-2001892-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | Ambit Biosciences Corporation (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007109120-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180256586-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | MDM2, CRBN, FLT3 | FLT3 3/4885RAD51 3562/4885LMNA 1546/4885 |
| US-20090131426-A1 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-UREA, COMPOSITIONS THEREOF, AND USES THEREWITH | OAT, TERT, TPMT | FLT3 797/4885RAD51 2890/4885LMNA 449/4885 |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | FLT3 210/4885RAD51 4704/4885LMNA 3036/4885 |
| US-20130005966-A1 | PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES | FLT4, FLT1, FLT3 | FLT3 3/4885RAD51 3466/4885LMNA 3287/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | FLT3 128/4885RAD51 4774/4885LMNA 1744/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | FLT3 3/4885RAD51 3562/4885LMNA 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.